Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
Bio-IT World November 2005 Charles Firneno	The Information Value Chain By looking at the evolution of pharma's information networks, strategies can be designed for IT solutions such as CRM, CTMS, AERSs, and business analytics software to deliver the highest possible value.
The Motley Fool April 20, 2011 Brandon Glenn	Growing CRO Demand Boosts Outlook for Kendle It's been rough going lately for Kendle.
The Motley Fool August 27, 2011 Michael Olsen	Rising Star Buy: More Icon Icon shares might not appreciate tomorrow, and they might decline more before they go up. But here is a rare value: a secular growth story at a stellar valuation.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool July 27, 2011 Michael Olsen	Rising Stars Buy: Icon Icon, the fourth-largest CRO, sits among the global elite and makes for a healthy investment.
The Motley Fool October 29, 2009 Robert Steyer	Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle.
The Motley Fool August 1, 2008 Brian Orelli	Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit.
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
Pharmaceutical Executive September 1, 2012 Roy F. Waldron	Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector?
The Motley Fool July 22, 2009 Robert Steyer	Canaries in the Drug Coal Mine Contract research organizations like Pharmaceutical Product Development and ICON reflect an ailing drug industry.
Pharmaceutical Executive January 1, 2009 Stan Bernard	Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms.
Pharmaceutical Executive September 1, 2008 Zhu Shen	Unleash the Dragon Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital.
Chemistry World May 19, 2008 Hepeng Jia	China's one stop research shop John Oyler has founded a string of startups in the US, but in 2005 he chose China as his base to launch BioDuro, a life sciences Contract Research Organisation.
Pharmaceutical Executive April 1, 2009 David Zuckerman	Make a Match Big Pharma is finally making a commitment to partner-based outsourcing.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
Pharmaceutical Executive June 1, 2012 Ben Comer	Disruption in the C-Suite Clayton Christensen, author of "The Innovator's Dilemma," offers to collaborate with pharma CEOs on solutions to the strategic impasse around flagging drug productivity.
Pharmaceutical Executive September 1, 2006	Thoughtleader: Small Cost, Big Win CEO J.J. Finkelstein discusses why outsourcing suits RegeneRx, how he manages to stay in control of operations, and why he's still able to sleep at night.
The Motley Fool March 15, 2005 Lawrence Meyers	Pharma's Outsourcing Elixir Pharmaceutical Product Development saves the drug companies money. Solid financials suggest it's a prescription that's working. Investors who do their due diligence may also find a few dollars earned in their brokerage accounts as well.
Pharmaceutical Executive May 1, 2007 Waseem Noor	Toolkit: How To Be a Better Partner Big pharmas and little biotechs have been getting hitched for years. Now it's time to add a little innovation to the relationship. Three new rules will keep the game exciting.
The Motley Fool January 31, 2011 Brian Orelli	Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities.
The Motley Fool July 30, 2009 Robert Steyer	Covance Advances Covance latest results produce more optimism than did some of its contract research peers.
The Motley Fool May 5, 2004 Brian Gorman	Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas.
Managed Care August 2004	MCOs, Drug Manufacturers Have Lots of PR Work to Do Managed care companies, and pharmaceuticals especially, receive disheartening numbers in a consumer satisfaction poll.
Food Processing January 2009 Dave Fusaro	Collective Wisdom on Outsourcing Our joint survey on contracting-out production, R&D and other functions finds a lot of mixed feelings.
Chemistry World September 7, 2011 Andrew Turley	First Pfizer Spinout at Sandwich Green shoots of recovery are starting to sprout at the Pfizer site in Sandwich, UK, with the first spinout opening its doors.
Bio-IT World April 16, 2004 Joel Hoffman	Taking the Trial Out of Clinical Outsourcing Make sure the vendor's standard operating procedures will mesh with your own, and then tirelessly work toward systems integration.
Pharmaceutical Executive February 1, 2011 Stergiopoulos et al.	Honing Reforms from Clinical Development Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities
The Motley Fool April 24, 2009 Robert Steyer	Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services.
The Motley Fool June 14, 2007 Ryan Fuhrmann	Dueling Fools: GlaxoSmithKline Bear Rebuttal There are better opportunities to use short-term pain and establish positions in pharmaceuticals with better long-term potential.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Chemistry World February 2012	Navigating the stormy seas of pharma In the pharmaceutical and biotech sector, quality navigation is becoming an essential process for identifying the best route to take in order to guide business effectively in a dramatically changing environment.
Pharmaceutical Executive March 1, 2013	China and the Emerging Markets Challenge: Why Big Pharma Must Embrace a New Strategy With health reform already tagged as a key domestic priority, their policies will pose new opportunities and challenges for Big Pharma companies active in China.
The Motley Fool July 15, 2004 Brian Gorman	Research Company's Stock Surges PPD's (formerly Pharmaceutical Product Development) second-quarter report isn't perfect, but long-term indicators look solid. The stock has risen as much as 14%.
Knowledge@Wharton	Encouraging the Development of Drugs for Poor, not Just Rich, Nations The current system rewards research into diseases that afflict rich countries, but creating new medicines for the rest of the world and finding ways to pay for them will demand new partnerships, according to panelists at the recent conference "Pharmaceutical Innovation in a Global Economy."
Pharmaceutical Executive June 1, 2011	Filling in the Bigger Picture Part II of The Avoca Group's 2011 CRO survey on clinical development outsourcing relationships.
Pharmaceutical Executive April 1, 2007 Walter Armstrong	Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom.
Information Today November 29, 2004 Paula J. Hane	Thomson Announces New Pharma Research Tool The Thomson Corp. is using the Online Information exhibition in London for the official launch of its new integrated research tool for the pharmaceutical and biotech industries.
Chemistry World September 11, 2014 Emma Stoye	Pharma sales 'will reach $1 trillion' in 2014 Global sales in the pharmaceutical industry are set to go over the $1 trillion mark this year, according to a report by Thomson Reuters.
The Motley Fool March 18, 2004 Brian Gorman	The Drug Cost Conundrum While drug prices continue to climb, the public and its representatives in government are demanding cheaper pharmaceuticals. The industry is not likely to find cover in Medicare biotechnology. Instead, investors should look for drug makers that are finding ways to operate leaner and meaner.
The Motley Fool August 1, 2007 Stan Huber	Fool Exclusive: An Interview With inVentiv Health CEO Eran Broshy Here, the pharmaceutical staffing, sales, and communications provider's CEO discusses the company, its clients and its investment outlook.
Bio-IT World May 2006 Mark D. Uehling	Bio-IT World CTMS Survey An online survey of the clinical trial management system market reveals some divergences between how the pharma/biotech folks and the contract research folks see the CTMS landscape. Are our respondents happy with the CTMS landscape?
The Motley Fool October 23, 2009 Robert Steyer	Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends.
The Motley Fool January 24, 2006 Stephen D. Simpson	Reddy, Set, Go! After a tough stretch, leading Indian pharmaceutical company Dr. Reddy's may be ready to move again. This is still a turnaround story, though, so investors unable or unwilling to assume above-average risk should probably steer clear.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
The Motley Fool August 13, 2007 Andrew R. Vaino	Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow.
Chemistry World May 26, 2015 Phillip Broadwith	Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt.